Spectrum Pharmaceuticals News

On Monday, February 13, Seattle Genetics will release its fourth quarter and year end results, and investors will get the first full-quarter sales data for Adcetris , the company's first marketed drug which was approved on August 19, 2011.

Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that an overview of the Company's business strategy will be given at the BIO CEO Investor Conference, being held at the Waldorf=Astoria Hotel in New York City.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia HENDERSON, Nev.-- --Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and ... (more)

Spectrum Pharmaceuticals Inc.'s fourth-quarter sales will match or beat the previous quarter's revenue, Chief Executive Officer Rajesh Shrotriya said.

Short sellers can give a quick and easy look into what the market is currently thinking about a stock - stocks seeing more shares shorted over time are being viewed more negatively, and vice-versa. To illustrate this, we ran a screen on the healthcare industry for stocks seeing the most significant increases in shares shorted month-over-month, ... (more)

Spectrum Pharmaceuticals hit a low of $13.50 on Thursday and traded with a 6.5% loss throughout most of the day.

Spectrum Pharma was upgraded by equities research analysts at Roth Capital from a "neutral" rating to a "buy" rating in a research note issued to investors on Thursday.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia HENDERSON, Nev.-- --Spectrum Pharmaceuticals announced that it has entered into an agreement to acquire licensing rights to market ZEVALIN injection for intravenous use outside ... (more)

Spectrum Pharmaceuticals Inc said it would acquire rights to market cancer drug Zevalin outside of the United States from German drugmaker Bayer for 19 million euros .

Spectrum Pharmaceuticals announces positive results. Zevalin is improving outcomes of high-risk lymphomas according to a paper published by Cancer.

McNicoll Lewis Vlak has published a research report on Spectrum Pharmaceuticals after the company reported positive results from Zevalin in the Journal 'Cancer'. In the report, MLV writes, "In several studies, we think Zevalin is beginning to demonstrate its potential for wide applicability across various sub-types of non-Hodgkin's lymphomas.

Spectrum Pharmaceuticals, Inc. Touts Lymphoma Drug Study Results; Stock Rises +Up 0.58 @ 10:46AM EST HENDERSON, Nev., Jan 23, 2012 -- --Publication in "Cancer" Shows Increasing Recognition and Importance of ZEVALIN in Improving Outcomes in the Treatment of Refractory High-Risk Lymphomas; --ZEVALIN is Currently Approved by the FDA and Marketed by ... (more)

The economy is improving, but stock investors already know this, says Paul R. La Monica at CNN Money .

Irvine, CA, January 20, 2012 - - Ernst & Young LLP is calling for nominations for the Ernst & Young Entrepreneur Of The Year 2012 Regional Awards, recognized as one of the most prestigious business award programs in the country.

Analysts at Auriga upped their price target on shares of Spectrum Pharma to $18.00 in a research report issued to clients and investors on Tuesday.